News and Events

Nutrinia Announces First Patient Enrolled in Phase III Trial

Proprietary Oral Formulation of Insulin to Treat Intestinal Malabsorption in Infants RAMAT-GAN, Israel and MORRISTOWN, N.J., Nov. 3, 2016  /PRNewswire/ — Nutrinia, Ltd. (“Nutrinia”) is pleased to announce the enrollment of the first patient in its FIT-04 study. Nutrinia is developing NTRA-2112 as a treatment for preterm infants with intestinal malabsorption.  NTRA-2112 is a novel oral […]

Nutrinia Announces $30 Million Series D Financing to Fund Clinical Development of Lead Product

RAMAT-GAN, Israel & MORRISTOWN, N.J.–(BUSINESS WIRE)–Nutrinia, Ltd. (“Nutrinia”), a company developing a proprietary oral formulation of insulin for intestinal malabsorption in preterm newborns and Short Bowel Syndrome (SBS) in infants, today announced the closing of a $30 million Series D financing to fund two pivotal trials for registration. TPG Biotech, the life science venture investment […]